The Disc-biotic platform is OxAG´s broad discovery and screening platform to identify the bioactive potential of drug candidates.

 This platform consists of various screening units.

Antimicrobial Unit screens against more than 140 different clinically relevant bacterial and fungal strains in nearly all indications, including multidrug resistant pathogens from all over the world. It allows to test for resistance and cross resistance, Mode of Action, and immune screening. The platform complies with European standards according to EUCAST (= European Committee for Antimicrobial Susceptibility Testing) and AFST (= Antifungal Susceptibility Testing) criteria based on the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The platform includes methods for resistance and cross resistance, MOA and immune screening.

Antiviral Unit screens compounds against respiratory virus like Rhinovirus, RSV, Influenza, Adeno and Corona. All screenings are cell-based, high throughput and regulated by internal GLP. OxAG uses it to perform studies in prophylactic and therapeutic setting to find candidates for both applications.    

Neurodegenerative Disease Unit uses innovative C. elegans models to identify compounds addressing age associated neurodegenerative disorders like Alzheimer´s disease, Parkinson´s diseases, Huntington disease and amyotrophic lateral sclerosis.